Zhejiang Sunflower to acquire assets, raise capital, diversify business

Zhejiang Sunflower Great Health Technology Co., Ltd. (SZSE:300111) plans to acquire 100% equity of Zhangzhou Cipux Material Technology Co., Ltd. and 40% equity of Zhejiang Beide Pharmaceutical Co., Ltd. This will be done through a combination of share issuance and cash payments. Concurrently, the company will raise supporting funds from up to 35 specific investors. The total amount will not exceed 100% of the asset acquisition’s share-based consideration. The number of shares issued will not surpass 30% of the company's total share capital post-acquisition.

The acquired assets, including high-end semiconductor materials and pharmaceutical products, are expected to diversify Zhejiang Sunflower’s business into strategic emerging industries, strengthening its profitability and asset quality.

The transaction requires shareholder approval, regulatory review by the Shenzhen Stock Exchange, and registration with the China Securities Regulatory Commission. As of September 19, 2025, the company's controlling shareholder, Wu Jianlong, released 30,000,000 pledged shares, representing 8.09% of his holdings and 2.33% of the company's total share capital. There is no flat position or forced transfer risk associated with the pledge release.

The company's stock, which was suspended on September 8, 2025, will resume trading on September 22, 2025. Definitive transaction prices and share numbers will be determined after the audit and appraisal of the target assets are complete.